ライフサイエンスコーパス: Fc

1 Fc-FcgammaR interactions are tightly regulated to contro

2 Fc-mediated antiviral activity has been implicated as a

3 Fc-SEMSs were successfuly deployed and removed in all of

4 lemented to analyze the interaction of Thy-1-Fc with nonpurified alphavbeta3-Fc integrin, whereby non

5 estimating specific rupture forces for Thy-1-Fc/alphavbeta3-Fc dissociation and calculating the kinet

6 /Fc, nonlytic IL-2/Fc, TGF-beta/Fc, or IL-10/Fc fusion proteins to promote chimerism to induce tolera

7 regulatory cytokine fusion proteins of IL-10/Fc, TGF-beta/Fc, or IL-2/Fc would enhance allogeneic bon

8 Fc (5- or 10-day treatment) or nonlytic IL-2/Fc (10-day treatment) fusion proteins to the conditionin

9 The combination of nonlytic IL-2/Fc and TGF-beta/Fc had a synergistic effect to promote e

10 TGF-beta/Fc and nonlytic IL-2/Fc exert a synergistic effect in promotion of alloengraf

11 n proteins of IL-10/Fc, TGF-beta/Fc, or IL-2/Fc would enhance allogeneic bone marrow cell (BMC) engra

12 Recipients were treated with lytic IL-2/Fc, nonlytic IL-2/Fc, TGF-beta/Fc, or IL-10/Fc fusion pr

13 re treated with lytic IL-2/Fc, nonlytic IL-2/Fc, TGF-beta/Fc, or IL-10/Fc fusion proteins to promote

14 analyzed the efficiency of factor H (FH)6-7/Fc, a novel antibacterial immunotherapeutic protein agai

15 FH6-7/Fc has previously been shown to enhance complement-depen

16 sized that activation of complement by FH6-7/Fc on the surface of Gram-positive bacteria such as S. p

17 genes, linked to the Fc region of IgG (FH6-7/Fc).

18 Furthermore, FH6-7/Fc, which binds to protein H and selected M proteins, di

19 A Fc-SEMS, 8 to 10 mm in diameter, was inserted to the str

20 In in vitro studies, Nogo-A-Fc failed to inhibit growth of lizard RGC axons.

21 of lizard RGC axons on substrates of Nogo-A-Fc, but not laminin.

22 On patterned substrates of Nogo-A-Fc, KT5720 caused restriction of axon growth to areas de

23 ion of axon growth to areas devoid of Nogo-A-Fc.

24 Signal integration between activating Fc receptors and inhibitory signal regulatory protein al

25 Gs with enhanced affinity for the activating Fc receptor FcgammaRIIIA due to afucosylated Fc glycans

26 Use of a soluble ActRIIB-Fc "trap," to block myostatin pathway signaling in norma

27 ACVR2B/Fc prevented the loss of muscle mass and strength, and t

28 ACVR2B/Fc, an inhibitor of the Activin Receptor 2B signaling, h

29 sed a soluble ActRIIB decoy receptor (ACVR2B/Fc) to test the effects of myostatin/activin A inhibitio

30 uscle and bone degeneration, and that ACVR2B/Fc prevents these derangements.

31 cancer cell growth by engaging high-affinity Fc receptors on monocytes and macrophages; however, the

32 An afucosylated Fc form (Pr20M) directed antibody-dependent cellular cyt

33 Fc receptor FcgammaRIIIA due to afucosylated Fc glycans and IgG1 subclass.

34 d, and suggest that it could be used for all Fc containing therapeutics (e.g. antibodies, bispecific

35 ific rupture forces for Thy-1-Fc/alphavbeta3-Fc dissociation and calculating the kinetic and transiti

36 ion of Thy-1-Fc with nonpurified alphavbeta3-Fc integrin, whereby nonspecific rupture events were cor

37 s into a hexameric coiled-coil bundle and an Fc-binding Protein A fragment, we generated the Hex nano

38 We generated an Fc tag-derived (Fc-d) E1E2 that was selectively captured

39 antibodies induced death of AML cells in an Fc receptor-dependent way in the absence of cytotoxic le

40 onal antibodies from different species in an Fc-specific fashion.

41 y therapy in pediatric BCP-ALL, we tested an Fc-engineered CD19 antibody carrying the S239D/I332E mut

42 (e.g. antibodies, bispecific antibodies, and Fc fusions) requiring lack of effector function or elimi

43 agocytosis of IgG-opsonized bioparticles and Fc receptor CD16 and CD32 surface levels, a function, to

44 tibodies traditionally requires both Fab and Fc domains of IgG.

45 ric fragment crystallizable (Fc) regions and Fc-fusion proteins are actively being explored as biomim

46 In contrast, Syk and Fc receptor-like 1 were downregulated.

47 hogens by immune cells triggers both TLR and Fc receptor signaling.

48 d a role for binding antibodies and antibody Fc-mediated effector functions.

49 oit these integrins as a target for antibody Fc effector functions in the context of cancer immunothe

50 ng cryoelectron microscopy of the SVV-ANTXR1-Fc complex.

51 s complement binding and fixation as well as Fc-gamma-dependent, antibody-dependent, cell-mediated cy

52 Au/Fc-PAMAM(G2)/FA and Au/Fc-PAMAM(G2)/BA based cytosensors

53 Au/Fc-PAMAM(G2)/FA and Au/Fc-PAMAM(G2)/BA based cytosensors showed extremely good

54 y 293 cells (HEK 293) as normal cells and Au/Fc-PAMAM(G2)/FA electrode showed two times better select

55 n of Eph-B-mediated signaling with Ephrin-B2/Fc showed improved fistula patency with less wall thickn

56 n autoantibody(+) NOD mice, continuous BAFFR-Fc treatment alone or in combination with anti-CD20 (des

57 ded no greater T1D protection than did BAFFR-Fc alone.

58 ice given transient late disease stage BAFFR-Fc monotherapy were rendered T1D resistant.

59 ted the protective effect of transient BAFFR-Fc monotherapy.

60 lso temporarily increased by transient BAFFR-Fc treatment, but not anti-CD20 therapy.

61 collective studies indicate transient BAFFR-Fc-mediated B lymphocyte depletion elicits long-term T1D

62 ing downstream of the B-cell receptor (BCR), Fc receptors (FcRs), and toll-like receptors.

63 : being a type I anti-CD20 mAb and not being Fc-optimized.

64 The addition of TGF-beta/Fc (5- or 10-day treatment) or nonlytic IL-2/Fc (10-day

65 TGF-beta/Fc and nonlytic IL-2/Fc exert a synergistic effect in pr

66 ic BMC engraftment is enhanced with TGF-beta/Fc fusion protein treatment.

67 combination of nonlytic IL-2/Fc and TGF-beta/Fc had a synergistic effect to promote engraftment and r

68 th lytic IL-2/Fc, nonlytic IL-2/Fc, TGF-beta/Fc, or IL-10/Fc fusion proteins to promote chimerism to

69 tokine fusion proteins of IL-10/Fc, TGF-beta/Fc, or IL-2/Fc would enhance allogeneic bone marrow cell

70 he carbohydrate moiety interconverts between Fc-bound and unbound forms, enabling enzymatic modificat

71 ular, which enables functionalization beyond Fc-binding.

72 The (R)-BINOL Fc phosphate gave Fc-rearranged phosphonate in 91% de.

73 ls are lithiated and rearranged, followed by Fc and N-heterocycles.

74 ggesting their protection may be mediated by Fc-FcR interactions.

75 ersion of the nanodot molecular occupancy by Fc-PEG chains can be reliably quantified, evidencing tha

76 05-10mugdL(-1) for both nanoconjugates: Fe@C-Fc-1 and Fe@C-Fc-2, in the presence and absence of the m

77 The obtained detection limit (LOD) for Fe@C-Fc-1 was found to be 0.60 and 0.10mugdL(-1) in the absen

78 agnetic field, respectively, whilst for Fe@C-Fc-2 was 0.4 and 0.07mugdL(-1) in the absence and presen

79 for both nanoconjugates: Fe@C-Fc-1 and Fe@C-Fc-2, in the presence and absence of the magnet, respect

80 ntact zone of T lymphocytes with rE-cadherin-Fc-coated beads.

81 nomic and phenotypic analyses of FCGR3A/CD16 Fc-receptor profiles were compared in CAV-positive (n=52

82 The CD16 (Fc-gamma receptor 3A [FCGR3A]) receptor was recently ide

83 c anti-HLA antibodies triggering their CD16a Fc receptors.

84 ostatic force between the positively charged Fc units and the negatively charged top electrode, but r

85 try, even though the ch14.18 scFv-gD chimera Fc bound to neuroblastoma cells expressing GD2.

86 rane sequence that interacts with the common Fc receptor gamma subunit to initiate immune signaling.

87 sed on molecular recognition of the constant Fc region.

88 Multimeric fragment crystallizable (Fc) regions and Fc-fusion proteins are actively being ex

89 spectively, and the fragment crystallizable [Fc] domain and Fcgamma receptor IIIalpha, respectively)

90 recipients and given a single dose of CTLA4-Fc at the time of transplant and 4doses of anti-CD154 mA

91 tau-associated antibodies and the cytosolic Fc receptor tripartite motif protein 21 (TRIM21).

92 formamide) or electron (decamethylferrocene (Fc*)) sources.

93 to H2O2 (93-99%) using decamethylferrocene (Fc*) as the reductant and acetic acid as the proton sour

94 Solving the crystal structure of the DEKK Fc region at a resolution of 2.3 A enabled detailed anal

95 We generated an Fc tag-derived (Fc-d) E1E2 that was selectively captured by protein G Se

96 ands, CD80 and CD86, and screened as dimeric Fc fusions directly in functional assays to identify var

97 ng the binding affinity of the Fc to diverse Fc receptor family members.

98 imulation with an EphB2 extracellular domain-Fc fusion protein (EphB2-Fc) induces RhoA activation and

99 , whereas all antibodies recognized Siglec-E-Fc on immunoblots, binding was dependent on intact disul

100 In vitro, MMP-7 inhibition and EC4-Fc administration significantly supressed human aortic V

101 at the combination of Mmp-7 deletion and EC4-Fc overexpression significantly increased AAA severity.

102 sly demonstrated that over-expression of EC4-Fc (truncated N-cadherin), or deletion of matrix-metallo

103 deletion and systemic over-expression of EC4-Fc reduced both proliferation and apoptosis.

104 formation, whereas adhesion to a 60-kPa Ecad-Fc PA gel induced Arp2/3-dependent lamellipodial protrus

105 Cell adhesion to a 30-kPa Ecad-Fc PA gel required Cdc42- and formin-dependent filopodia

106 agglutinin (WGA) was linked to the effector Fc region of murine IgG2a.

107 e SEFL modifications successfully eliminated Fc-associated effector binding and functions.

108 We used the engineered Fc domains to demonstrate in vitro and in mouse models t

109 e Fc domain (e.g., E345K or E430G) enhancing Fc:Fc interactions, hexamer formation, and CDC after Ab

110 ts for nnAb-resistant viruses in an entirely Fc-dependent manner.

111 xtracellular domain-Fc fusion protein (EphB2-Fc) induces RhoA activation and enhances the motility as

112 led monolayers with Fc-C identical withC-Fc (Fc, ferrocenyl) termini.

113 tate oxidation potential of -2.43 V vs Fc(+)/Fc, the Cr(0) complex is a very strong photoreductant.

114 quasi-reversible oxidation waves (vs. Fc(+)/Fc) at 0.58-0.75 V and reduction waves at -0.97 to -1.16

115 oiety linked to an electron-donor ferrocene (Fc) unit supported by ultraflat template-stripped Au and

116 l molecular system, consisting of ferrocene (Fc) labeled polyethylene glycol (PEG) disulfide chains.

117 rocene derivatives: ferrocenecarboxaldehyde (Fc-1) and ferrocenecarboxaldehyde oxime (Fc-2).

118 In conclusion, FH-Fc chimeric proteins could serve as adjunctive treatment

119 lation alters the affinity of antibodies for Fc receptors, evidence suggests that glycosylation is a

120 ycoforms on the IgG crystallizable fragment (Fc) dictate these divergent functions.

121 uR receptor for the crystallizable fragment (Fc) of immunoglobulin M (IgM) can function as a cell-sur

122 Engineered crystallizable fragment (Fc) regions of antibody domains, which assume a unique a

123 Antisera from Fc-d E1E2-immunized mice exhibited stronger competition

124 related pathway activation but with further Fc macrophage activation, cell death and turnover and ac

125 I (FVIII) with extended half-life (eg, FVIII-Fc and PEGylated FVIII), monoclonal antibodies targeting

126 The (R)-BINOL Fc phosphate gave Fc-rearranged phosphonate in 91% de.

127 plasma circulation (>72 h), followed by GCSF-Fc (>48 h) and GCSF ( 24 h), which is consistent with th

128 st recovery of neutrophils, followed by GCSF-Fc and GCSF.

129 The EC50 dose-response curves for GCSF, GCSF-Fc and PEG-GCSF were 37 +/- 12 pM, 75 +/- 13.5 pM and 46

130 The bioactivities of GCSF-Fc and PEG-GCSF were similar to native GCSF using the mo

131 he Fc domain of IgG1 at the C terminus (GCSF-Fc) and with the maltose binding protein (MBP) tag at th

132 In summary, the GCSF-Fc purified from E. coli was not as efficient as PEG-GCS

133 polyamidiamine dendrimers second generation (Fc-PAMAM (G2)), after which electrodes were modified wit

134 ulaglutide, a glucagon-like peptide 1 (GLP1)-Fc fusion protein.

135 Hexa-Fc contains two N-linked sites at Asn-77 (equivalent to

136 We have generated a hexameric-Fc fusion protein (hexameric-Fc) and tested the conseque

137 et phagocytosis several days after hexameric-Fc dosing.

138 l we observed a short half-life of hexameric-Fc but were nevertheless able to observe inhibition of p

139 In vitro engagement of hexameric-Fc with FcgammaRs showed complex binding interactions th

140 ted a hexameric-Fc fusion protein (hexameric-Fc) and tested the consequences of multi-valent Fcgamma-

141 ion and refolding of the hole-hole homodimer Fc.

142 asymmetric structure within the homodimeric Fc polypeptide, enable completely selective binding to t

143 gage with FcgammaRIIIA, as well as the human Fc gamma RII subset.

144 The binding of human IgG1 to human Fc gamma receptors (hFcgammaRs) is highly sensitive to t

145 potency-optimized CTLA4 moieties with human Fc variants conferring extended plasma t1/2 In a cynomol

146 essed, and the role of the high-affinity IgE Fc receptor (FcepsilonRI) in allergic sensitization was

147 ex between an omalizumab-derived Fab and IgE-Fc, with one Fab bound to each C3 domain.

148 heavy-chains in the asymmetrically bent IgE-Fc.

149 present the crystal structure of a CD23/IgE-Fc complex and conduct isothermal titration calorimetric

150 Free IgE-Fc adopts an acutely bent structure, but in the complex

151 erplay between receptor binding sites in IgE-Fc and their affinities, the understanding of which may

152 ctin-like "head" domains of CD23 bind to IgE-Fc with affinities that differ by more than an order of

153 The inhibitory low-affinity IgG Fc-receptor FcgammaRIIB is co-expressed on allergic effe

154 eering technology is a powerful tool for IgG Fc (fragment cystallizable) N-glycosylation remodeling.

155 y to systemic anaphylaxis that relies on IgG Fc receptors (FcgammaRs).

156 expressing both hPF4+ and human platelet IgG Fc receptor IIA (FcgammaRIIA), infusion of the HIT-like

157 Recent studies indicate that IgG Fc-FcgammaR interactions are dynamically regulated durin

158 d by the structural heterogeneity of the IgG Fc domain, stemming from differences in the primary amin

159 w, we discuss the mechanisms that govern IgG-Fc receptor interactions, highlighting the diversity of

160 vealing a nearly complete overlap of the IgG-Fc binding site in FcRn by complementarity-determining r

161 e demonstrated that aglycosylated human IgG1 Fc variants can engage the human FcgammaRII class of the

162 of sequentially truncated high-mannose IgG1 Fc glycoforms, we found that the C'E loop and the Cgamma

163 ncated glycoforms, suggesting a role of IgG1 Fc N-glycan in optimizing the interface with the Fc rece

164 ns can modulate the binding affinity of IgG1 Fc to Fc gamma receptors, but it is unclear how the stru

165 The Fc region of human IgG1 (IgG1-Fc) can be engineered into multimeric structures (hexa-F

166 sn-297 on the structure and function of IgG1-Fc is well documented; however, whether the N-linked gly

167 half-life extension by fusion of A4 to IgG2a Fc (A4Fc) overcame the issue of an antigen sink or, in t

168 p pH changes in order to mimic properly IgGs Fc domain/FcRn receptor interaction.

169 ced IgG signaling through type I and type II Fc receptors is required for the control of proinflammat

170 ILT3.Fc inhibited the growth of CD166(+) tumor cell lines (TC

171 rkat acute T cell leukemia, which binds ILT3.Fc to its membrane.

172 The mechanism underlying the effect of ILT3.Fc on tumor cell growth involves inhibition of the p70S6

173 nucleofection abolished the capacity of ILT3.Fc to inhibit CD4(+) Th cell proliferation and to induce

174 ies did not enhance the infection of DENV in Fc gamma receptor-expressing cells, offsetting the conce

175 uced FcgammaRI effector functions, including Fc receptor gamma-chain signaling and intracellular calc

176 ineate the effects of IgG and its inhibitory Fc receptor, FcgammaRIIb, on both de novo allergen sensi

177 he periphery, upregulation of the inhibitory Fc gamma receptor (FcgammaR) IIb at the tumor site preve

178 ipartite motif (TRIM) 21 as an intracellular Fc receptor linking cytosolic antibody recognition to th

179 (ferrocenylmethyl) trimethylammonium iodide (Fc(+)), a photo-induced electron transfer (PET) fluoresc

180 ce is naturally coated with IgG bound by its Fc domain to the Fcgamma receptor CD16a.

181 nd pharmacokinetics of recombinant factor IX Fc fusion protein (rFIXFc) in previously treated paediat

182 three mAb subunits of approximately 25 kDa: Fc/2, Fd', and LC.

183 IgG-lacking Fc redistributes AQP4 within the plasma membrane and ind

184 prisingly, despite the presence of the large Fc tag, Fc-d E1E2 formed heterodimers similar to those f

185 FcgammaRIIIa-158F allotype displays a lower Fc binding affinity) using the TaqMan single nucleotide

186 Redox separations for multiple Fc molecules are based on electrostatic interactions.

187 computational modeling to identify multiple Fc variant pairs that drive efficient heterodimerization

188 rearrangements (apFr) of P(O)(OFc)n(EAr)3-n (Fc = Fe(eta(5)-C5H5)(eta(5)-C5H4); E = O; Ar = phenyl, n

189 onal studies by antigen binding and neonatal Fc receptor (FcRn) binding correlated very well with the

190 involvement of immune complexes and neonatal Fc receptor (FcRn) in the emergence of ADAs in the case

191 The endothelial cellular neonatal Fc receptor (FcRn) has been suggested to play a central

192 across the placenta by binding the neonatal Fc receptor (FcRn) expressed within the endosomes of the

193 We also identify that the neonatal Fc receptor (FcRn) is upregulated in the cornea followin

194 The neonatal Fc receptor FcRn plays a critical role in the traffickin

195 by instructing T reg formation via neonatal Fc receptor (FcRn)-mediated transfer and uptake of aller

196 interaction is pH-insensitive unlike normal Fc interactions and how serum albumin levels are unaffec

197 F(ab')2 but not Fc fragments of IVIG induced death of human neutrophils,

198 As a result, blockade of Fc-mediated function is an important strategy for the co

199 Combination of Fc-SEMS and plastic stent(s) is technically feasible and

200 ed by signal blocking or the cytotoxicity of Fc-driven innate immune effector functions.

201 This caused a disruption of Fc-binding and phagocytosis.

202 interactions, highlighting the diversity of Fc receptor-mediated effector functions that regulate im

203 Manipulation of Fc-FcgammaR interactions to specifically activate distin

204 based on the immunomodulatory properties of Fc-FcgammaR interactions.

205 protection is antibody mediated and based on Fc effector functions.

206 d stability studies enabled selection of one Fc variant pair dubbed "DEKK" consisting of substitution

207 n (OPG)-immunoglobulin fragment complex (OPG-Fc) completely restore the function of fast-twitch exten

208 scles but is rescued by the injection of OPG-Fc.

209 nd cardiac tissues, we hypothesized that OPG-Fc, a bone and skeletal muscle protector, acts synergist

210 at position 435 (H435) provides for optimal Fc-IgG binding.

211 CetuGEX, an antibody with optimized Fc glycosylation targeting the same epitope as cetuximab

212 o] and [AcOH], but no dependence on [O2] or [Fc*].

213 pus model, treatment with an antagonist Ox40:Fc fusion protein significantly delayed the onset of sev

214 de (Fc-1) and ferrocenecarboxaldehyde oxime (Fc-2).

215 s deficient in Mincle or its adapter protein Fc receptor gamma chain (FcRgamma) produced severely red

216 present on the conserved HC constant region (Fc).

217 ted that broadly reactive antibodies require Fc-Fc gamma receptor interactions for optimal protection

218 iated enhancement of IFN production required Fc gamma receptor engagement, bypassed fusion, and initi

219 ligomerization of sP-selectin or sP-selectin-Fc was required to trigger formation of neutrophil extra

220 rtion of mouse immunoglobulin G (sP-selectin-Fc).

221 Dimeric sP-selectin-Fc, but not monomeric sP-selectin, triggered integrin-de

222 Injecting sP-selectin-Fc, but not sP-selectin, into mice augmented integrin-de

223 e shifts at the interface, yielding a stable Fc conformation very similar to that in wild-type IgG.

224 Fully covered self-expandable metal stents (Fc-SEMSs) have a challenging use in the treatment of ana

225 y, despite the presence of the large Fc tag, Fc-d E1E2 formed heterodimers similar to those formed by

226 ing anti-HIV-1 antibodies that revealed that Fc-FcgammaR interactions are required to achieve full th

227 Antisera from immunized mice showed that Fc-d E1E2 elicited anti-E2 antibody titers and neutraliz

228 The Fc domain of IgG monoclonal antibodies (mAbs) contains t

229 The Fc region of human IgG1 (IgG1-Fc) can be engineered into

230 The Fc-region of monoclonal antibodies against TNF has immun

231 ectron transfer between the nanodots and the Fc heads displays some quantifiable variability but that

232 zyme, the biotherapeutic filgrastim, and the Fc part of immunoglobulin G1.

233 controlled through interactions between the Fc region and two principal cell surface receptors Fceps

234 NK cells bind the Fc portion of IgG via CD16a and execute Ab-dependent cel

235 dritic cells (DC), which was mediated by the Fc receptor and was specific to trastuzumab.

236 igenic recognition to block virus entry, the Fc domain interacts with diverse types of Fcgamma recept

237 types of Fcgamma receptors (FcgammaRs), the Fc domain of immunoglobulin G (IgG) mediates a wide spec

238 mpact of the immunogenicity derived from the Fc and variable domains.

239 We identified single-point mutations in the Fc domain (e.g., E345K or E430G) enhancing Fc:Fc interac

240 ites at Asn-77 (equivalent to Asn-297 in the Fc of IgG1) and Asn-236 (equivalent to Asn-563 in the ta

241 at position 1 (equivalent to Asp-221 in the Fc of IgG1) dramatically enhances overall sialic acid co

242 histidine residues His292 and His440 in the Fc region and His231 in the hinge region of the IgG1 mAb

243 Several amino acid changes in the Fc region have been reported to silence or reduce the ef

244 ns (T307P, L309Q, and Q311R or "TLQ") in the Fc region of human IgG1 which disrupt interaction with p

245 absolute quantification of oxidation in the Fc region of hydrogen peroxide-stressed Rituximab, using

246 Cys233 in the hinge region and Lys297 in the Fc region.

247 s (FcgammaR), and whether the absence of the Fc core fucose (which increases binding to FcgammaRIIIa)

248 ts were attributed to hyposialylation of the Fc glycan, and IgG from T2DM patients was also hyposialy

249 activity is attributed to sialylation of the Fc glycan.

250 nstrating that N-linked glycosylation of the Fc is not a strict requirement for hFcgammaR engagement.

251 enhances overall sialic acid content of the Fc multimers.

252 h CTLA4-Ig, a fusion protein composed of the Fc region of IgG1 and the extracellular domain of CTLA4

253 Affinity purification and removal of the Fc tag from E1E2 resulted in an antigen with a nearly id

254 ons by affecting the binding affinity of the Fc to diverse Fc receptor family members.

255 glycosylation site at asparagine 297 of the Fc, with deglycosylation resulting in a complete loss of

256 n immune response through the control of the Fc-associated glycan structure and Ig subclass compositi

257 well as the structure and composition of the Fc-associated N-linked glycan.

258 pacity of affinity resins for capture of the Fc-tagged rE1E2, we anticipate that our method will prov

259 tal complexes with histidine clusters on the Fc domain.

260 Here, we show the Fc domain of IgG alone mediates recognition and clearanc

261 mmaRIIB to stimulatory FcgammaRs through the Fc domains of an anti-FcgammaRIIB mAb induces and then s

262 or as a disulfide-linked dimer fused to the Fc portion of mouse immunoglobulin G (sP-selectin-Fc).

263 om autolysins and lysins can be fused to the Fc region of human IgG, creating a fully functional homo

264 d 7) that bind to S. pyogenes, linked to the Fc region of IgG (FH6-7/Fc).

265 7 and approximately 85% payload bound to the Fc region, presumably to histidine residues.

266 ut remains constant at reverse bias when the Fc units are neutral and interact weakly with the positi

267 To investigate whether the Fc domain of HJ8.5 is required for the therapeutic effec

268 come this bottleneck, we fused GCSF with the Fc domain of IgG1 at the C terminus (GCSF-Fc) and with t

269 -glycan in optimizing the interface with the Fc receptor for efficient binding.

270 of the IgG isotype are glycosylated in their Fc domain at a conserved asparagine at position 297.

271 allergens due to a desensitization of their Fc epsilon receptor pathway.

272 ector functions, through engagement of their Fc-gamma receptors.

273 o impact mucosal transmission events through Fc-gamma receptor (FcgammaR)-mediated inhibition.

274 xamined the interaction between the anti-TNF Fc-region and Fcgamma receptors (FcgammaR), and whether

275 modulate the binding affinity of IgG1 Fc to Fc gamma receptors, but it is unclear how the structural

276 Consequently, soluble gp130 fused to Fc transgenic mice lacking IL-6 trans-signaling are larg

277 magnitude superior to that of dimeric TRAIL-Fc, but also manifests more favorable pharmacokinetic an

278 hat may effectively substitute for wild-type Fc.

279 Upon Fc receptor activation, Src-family kinase signaling lead

280 stituents and produced interferon-gamma upon Fc-receptor engagement but not following combined interl

281 ings demonstrate the ability of multi-valent Fc-based therapeutics to interfere with FcgammaR functio

282 ion at a very mild potential (-0.16 V versus Fc(0/+)) in acetonitrile.

283 de) with an onset potential near -1 V versus Fc(0/+).

284 at -0.4 V and Co(I) at -1.0 to -1.3 V versus Fc(0/+).

285 3 also induced cytotoxicity in AML cells via Fc-effector function.

286 Env Abs can also exert antiviral effects via Fc-mediated effector mechanisms or as cytotoxic immunoco

287 gh the Fab domain to signal transduction via Fc-Fc receptor interactions.

288 ited-state oxidation potential of -2.43 V vs Fc(+)/Fc, the Cr(0) complex is a very strong photoreduct

289 scharge cycling at low potential (-1.21 V vs Fc/Fc(+)) to a 95% state-of-charge without detectable ca

290 xhibit quasi-reversible oxidation waves (vs. Fc(+)/Fc) at 0.58-0.75 V and reduction waves at -0.97 to

291 WGA-Fc opsonization increased fungal phagocytosis, as well a

292 Administration of WGA-Fc also dramatically diminished pulmonary inflammation.

293 Hence, the opsonic activity of WGA-Fc effectively modulates fungal cell recognition and pro

294 Prophylactic administration of WGA-Fc fully protected mice against H. capsulatum, correlati

295 Therefore, we propose WGA-Fc as a potential "pan-fungal" therapeutic that should b

296 While Fc undergoes one, the Ph-based apFr depends on temperatu

297 at Asn-297 is critical for interactions with Fc receptors and complement and that glycosylation at As

298 ), whereas IgG subclasses are monitored with Fc-specific monoclonal whole IgG (FcMonoIgG).

299 0(5) based on self-assembled monolayers with Fc-C identical withC-Fc (Fc, ferrocenyl) termini.

300 sembled monolayers with Fc-C identical withC-Fc (Fc, ferrocenyl) termini.